Baltimore sues J&J for spinning up a 'sham' Zytiga patent to fend off generics

Johnson & Johnson's blockbuster cancer drug Zytiga only recently lost its shield against generic competition, and according to a new lawsuit, that’s because J&J used underhanded tactics to keep copycat rivals at bay.